Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Background Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis ar...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Postow, Igor Puzanov, Suthee Rapisuwon, Michael A. Davies, Zeynep Eroglu, Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, John P. Greer, Douglas Johnson
Format: Article
Language:English
Published: BMJ Publishing Group 2017-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/5/1/8.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/5/1/8.full

Similar Items